Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Alar Pharmaceuticals's Enterprise Value is NT$5,522.78 Mil.
Alar Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-78.89 Mil. Therefore, Alar Pharmaceuticals's EV-to-EBIT ratio for today is -70.01.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Alar Pharmaceuticals's Enterprise Value is NT$5,522.78 Mil.
Alar Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-74.02 Mil. Therefore, Alar Pharmaceuticals's EV-to-EBITDA ratio for today is -74.61.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Alar Pharmaceuticals's Enterprise Value is NT$5,522.78 Mil.
Alar Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was NT$2.75 Mil. Therefore, Alar Pharmaceuticals's EV-to-Revenue ratio for today is 2,006.10.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Alar Pharmaceuticals (ROCO:6785) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Alar Pharmaceuticals's current Enterprise Value is NT$5,522.78 Mil.
Alar Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-78.89 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Alar Pharmaceuticals's current Enterprise Value is NT$5,522.78 Mil.
Alar Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-74.02 Mil.
Alar Pharmaceuticals's current Enterprise Value is NT$5,522.78 Mil.
Alar Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$2.75 Mil.
Alar Pharmaceuticals's current Enterprise Value is NT$5,522.78 Mil.
Alar Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-171.03 Mil.
Alar Pharmaceuticals's current Enterprise Value is NT$5,522.78 Mil.
Alar Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-171.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alar Pharmaceuticals Enterprise Value Related Terms
Alar Pharmaceuticals Enterprise Value Historical Data
* Premium members only.
The historical data trend for Alar Pharmaceuticals's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6785 vs ZTS, UTHR: Enterprise Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alar Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alar Pharmaceuticals Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alar Pharmaceuticals's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Alar Pharmaceuticals's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Alar Pharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of NT$5,522.78 Mil mean?
Alar Pharmaceuticals (ROCO:6785) has a Enterprise Value of NT$5,522.78 Mil as of Jul. 13, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Alar Pharmaceuticals and its competitors.
Is Alar Pharmaceuticals' Enterprise Value too high?
Alar Pharmaceuticals' current Enterprise Value is NT$5,522.78 Mil. Overall, Alar Pharmaceuticals has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alar Pharmaceuticals' Enterprise Value compare to ZTS and UTHR?
Alar Pharmaceuticals' Enterprise Value of NT$5,522.78 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Alar Pharmaceuticals and its competitors. Alar Pharmaceuticals's current Enterprise Value is NT$5,522.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alar Pharmaceuticals (ROCO:6785) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$90.64, compared to a current price of NT$117.00 — trading 29.1% above its estimated fair value. The current Enterprise Value is NT$5,522.78 Mil. Alar Pharmaceuticals' overall GF Score™ is 52/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Alar Pharmaceuticals (ROCO:6785), the current Enterprise Value is NT$5,522.78 Mil as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alar Pharmaceuticals (ROCO:6785) Overvalued in 2026?
Based on GuruFocus' analysis, Alar Pharmaceuticals stock appears to be overvalued.
The current stock price of NT$117.00 is trading 29.1% above its estimated GF Value™ of NT$90.64.
GuruFocus considers Alar Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for ROCO:6785:
Enterprise Value: NT$5,522.78 Mil
GF Value™: NT$90.64 vs. price of NT$117.00 (29.1% above fair value)
No single metric tells the full story. See the ROCO:6785 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alar Pharmaceuticals Inc is a drug development company mainly engaged in the research and development of new drugs, sales of western pharmaceuticals, and medical devices. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and depressive disorder. The company currently has only a new drug development division, and its product pipeline comprises various drug candidates such as ALA-1000 (Buprenorphine), ALA-1300, ALA-2000 (Naltrexone), ALA-3000 (Ketamine), ALA-4000 (Apomorphine), and ALA-5000 (Third-generation antipsychotic). Geographically, the company generates maximum revenue from the USA and also has its presence in Taiwan and the United Kingdom.
52GF Score
Get the complete analysis for ROCO:6785
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6785 has been successfully added to your 
